arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Decoy Therapeutics Inc.

DCOY
$1.12 ▲ +0.02 (+2.27%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
8
Health
Poor
Bearish
auto_awesome

Analytical Summary

Decoy Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -48.1% ↘
FCF / Share $-4.99 ↗
Trailing P/E —
Price / Book 0.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$227.63K
— —
Net Income Profit after all expenses
$-2.22M
↓ -30.1% —
Operating Margin Operating profit as % of sales
-142.2%
↓ -19.7% —
FCF / Share Free cash flow per share
$-4.99
↑ +8.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
2
Financial Health ↓
3
Cash Quality ↓
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 51 quarters